GlassScriptPhysician profile
William J Scott
NPI 1730116724
$1,701.98
in general payments reported to CMS, 2019-2025
24 companies · $377 in 2025
The $377 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $493 · 2020: $104 · 2022: $161 · 2023: $109 · 2024: $458 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $944.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $395.97 | 2019-2024 | Stiolto Respimat, Spiriva Respimat |
| Pfizer INC. | $227.55 | 2019-2025 | |
| Lilly USA, LLC | $156.10 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $130.94 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Ceribell, INC. | $110.78 | 2024 | Pocket Eeg Device |
| Abbvie INC. | $110.34 | 2022-2025 | |
| Glaxosmithkline, LLC. | $91.75 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $69.04 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $59.73 | 2020-2024 | Farxiga, Breztri |
| E.R. Squibb & Sons, L.L.C. | $34.95 | 2024-2025 | Eliquis |
| Sanara Medtech INC. | $33.23 | 2022 | |
| Xeris Pharmaceuticals, INC. | $32.83 | 2023-2025 | Gvoke Hypopen |
| Exact Sciences Corporation | $31.65 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $28.14 | 2020-2023 | Xarelto |
| Phathom Pharmaceuticals, INC. | $24.94 | 2025 | Voquezna |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $21.00 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.74 | 2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $20.46 | 2025 | Fanapt, Hetlioz |
| Amneal Pharmaceuticals LLC | $19.79 | 2025 | Crexont |
| Bayer Healthcare Pharmaceuticals INC. | $19.77 | 2023 | |
| Dynavax Technologies Corporation | $17.85 | 2025 | Heplisav-B |
| Seqirus USA INC | $17.19 | 2025 | Flucelvax, Fluad |
| Abbott Laboratories | $14.63 | 2019 | |
| Allergan, INC. | $12.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.